Galanin immunoreactivity in human CSF: studies in eating disorders and Alzheimer's disease. 1988

W H Berrettini, and W H Kaye, and T Sunderland, and C May, and H E Gwirtsman, and A Mellow, and A Albright
National Institute of Mental Health, Bethesda, Md.

Galanin is a peptide which stimulates feeding behavior in animals and is found within those basal forebrain cholinergic neurons which degenerate in Alzheimer's disease. Galanin was measured in cerebrospinal fluid (CSF) by radioimmunoassay. The nature of the immunoreactivity was characterized chromatographically as authentic galanin. CSF galanin levels were determined in subjects with Alzheimer's disease, involutional depression, anorexia nervosa and bulimia. No differences between any diagnostic group and age and sex-matched controls were found.

UI MeSH Term Description Entries
D008297 Male Males
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D002032 Bulimia Eating an excess amount of food in a short period of time, as seen in the disorder of BULIMIA NERVOSA. It is caused by an abnormal craving for food, or insatiable hunger also known as "ox hunger". Binge Eating,Bulimias,Eating, Binge
D003865 Depressive Disorder, Major Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5) Depression, Involutional,Major Depressive Disorder,Melancholia, Involutional,Paraphrenia, Involutional,Psychosis, Involutional,Depressive Disorders, Major,Involutional Depression,Involutional Melancholia,Involutional Paraphrenia,Involutional Paraphrenias,Involutional Psychoses,Involutional Psychosis,Major Depressive Disorders,Paraphrenias, Involutional,Psychoses, Involutional
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

W H Berrettini, and W H Kaye, and T Sunderland, and C May, and H E Gwirtsman, and A Mellow, and A Albright
March 1989, Neuroscience letters,
W H Berrettini, and W H Kaye, and T Sunderland, and C May, and H E Gwirtsman, and A Mellow, and A Albright
August 1992, Acta neurologica Scandinavica,
W H Berrettini, and W H Kaye, and T Sunderland, and C May, and H E Gwirtsman, and A Mellow, and A Albright
December 1988, Journal of neurochemistry,
W H Berrettini, and W H Kaye, and T Sunderland, and C May, and H E Gwirtsman, and A Mellow, and A Albright
August 1990, Annals of neurology,
W H Berrettini, and W H Kaye, and T Sunderland, and C May, and H E Gwirtsman, and A Mellow, and A Albright
May 1987, Biochemical and biophysical research communications,
W H Berrettini, and W H Kaye, and T Sunderland, and C May, and H E Gwirtsman, and A Mellow, and A Albright
May 1995, Journal of neuropathology and experimental neurology,
W H Berrettini, and W H Kaye, and T Sunderland, and C May, and H E Gwirtsman, and A Mellow, and A Albright
September 1985, Biological psychiatry,
W H Berrettini, and W H Kaye, and T Sunderland, and C May, and H E Gwirtsman, and A Mellow, and A Albright
April 1994, Journal of neurochemistry,
W H Berrettini, and W H Kaye, and T Sunderland, and C May, and H E Gwirtsman, and A Mellow, and A Albright
January 2014, Advances in clinical chemistry,
W H Berrettini, and W H Kaye, and T Sunderland, and C May, and H E Gwirtsman, and A Mellow, and A Albright
December 1989, Brain research,
Copied contents to your clipboard!